RECENT NEWS

A human challenge trial supported by the National Institute for Health and Care Research (NIHR)has shown that a new vaccine could offer better protection against whooping cough.

The UK Health Security Agency (UKHSA) has identified a new recombinant mpox virus in England in an individual who had recently travelled to Asia.

South Korean molecular diagnostics firm Seegene has announced the establishment of a new subsidiary in France to reinforce its European presence and support global sales expansion.

Roche has announced it has received the CE Mark for its cobas BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collected using the cobas PCR Media proprietary tube.

A newly published study has identified 'confounders' interfering with cancer signals, key physiological factors that can interfere with cancer-associated cell-free DNA (cfDNA), offering a foundation for improving the accuracy of liquid biopsy tests.

Randox has announce that its pioneering genetic test for type 1 diabetes (T1D) risk has received CE marking, the first regulatory approval of its kind anywhere in the world. The test, developed by Randox in collaboration with the University of Exeter, received regulatory UK Conformity Assessed (UKCA) approval in early 2024.

Lab Thread, a UK-based life science software company, has announced the beta launch of its flagship unified laboratory software platform.

Magentus, a provider of healthcare technology across the UK and Australia, has announced the acquisition of Labflow, a modern, cloud-native suite of pathology software products.

Roche’s first point-of-care test for the diagnosis of whooping cough (pertussis) and other Bordetella infections, has been granted US Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver, in addition to CE IVDR certification.

The British In Vitro Diagnostic Association (BIVDA) has announced the appointment of David Thorne as BIVDA’s Head of NHS Policy.

Healthcare AI firm Owkin has shared validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitised breast cancer pathology slides.

BD (Becton, Dickinson and Company) has announced the global commercial release of new configurations of cell analysers featuring breakthrough spectral and real-time cell imaging technologies, enabling more laboratories in academia, pharma and biotech – across scales, needs and budgets – to advance discoveries in immunology, cancer immunotherapy and cell biology.

The UK’s clinical immunology and allergy workforce is under severe strain, with consultant shortages leaving some services extremely fragile, according to a new report by the British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN).

A study of the human nasal microbiome has allowed scientists to rethink how bacterial communities interact in the nose.

The Department of Health and Social Care (DHSC) has published its HIV Action Plan for England, 2025 to 2030, which sets out how the government will reach its ambition of ending new HIV transmissions by 2030.

The Institute of Cancer Research (ICR), has responded to the draft recommendation from the National Screening Committee (NSC) to implement a targeted prostate cancer screening programme for men with a confirmed BRCA1 and BRCA2 variant.

The UK National Screening Committee (NSC) has opened a public consultation on prostate cancer screening, following its decision to not recommend population screening.

A new study led by the University of Cambridge and the University of Glasgow has discovered that bird influenza viruses are a particular threat to humans because they can replicate at temperatures higher than a typical fever, one of the body’s ways of stopping viruses in their tracks.

Baroness Nicola Blackwood has been appointed as Chair of the Health Data Research Service (HDRS) a new service which aims to streamline NHS data access for approved researchers to develop new medicines and therapies.

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria.